Active financing in the domestic medical and health field: 20 financings in one week, with a total financing of over 1.2 billion

Recently, financing in the domestic medical and health sector has remained active
.
According to incomplete statistics in the industry, in just one week (4.
9-4.
14), there were 20 financing events in the medical and health sector, with a total financing of over 1.
2 billion yuan, reaching 1.
226 billion yuan
.
The companies involved include Antikang Bio, Belair Bio, Xinyue Medical, Saihe Medical, Maibang Bio,
etc.
Active financing in the domestic medical and health field: 20 financings in one week, with a total financing of more than 1.
2 billion (Image source: Pharmaceutical Network) From the perspective of financing rounds, there are 5 rounds B and B+, 4 rounds A and A+, and Pre- 3 A rounds, 3 angel rounds, 4 strategic investments, and 1 seed round
.
Investors include Cornerstone Capital, Sequoia China, Northern Lights Capital, Huayi Capital, SDIC Ventures, DT Capital,
etc.
In the medical and health subdivision track, innovative drugs, in-vitro diagnostics, and interventional medical devices were more sought after by investors during the week
.
It can be found that these subdivided tracks are also several popular areas at present
.
For example, in the innovative drug industry, in recent years, benefiting from the promotion of a series of policies to support pharmaceutical innovation, the pace of transformation and upgrading of the domestic pharmaceutical industry has accelerated, the R&D investment of pharmaceutical companies has continued to increase, and the prosperity of the innovative drug industry has gradually warmed up
.
The role of in vitro diagnosis in the prevention, diagnosis and treatment of human diseases has become increasingly prominent, and it has become an increasingly important part of ensuring human health
.
With the intensification of aging, the introduction of a series of favorable policies, and the accelerated pace of substitution of domestic products for imports, the domestic in vitro diagnostic industry has broad prospects for development
.
The data shows that the scale of China's in vitro diagnostics market has reached 80 billion yuan in 2019, and it is expected to increase to 288.
2 billion yuan by 2030, and its proportion in the global market will be greatly increased
.
Similarly, there are interventional medical devices.
With the continuous improvement of disease detection rate and diagnosis rate in the domestic interventional field, as well as the aging of the population and the continuous improvement of residents' health awareness, my country's interventional medical device industry has a huge market development space.

.
Judging from the number of financing companies during the week, there are 4 innovative drug companies that have been invested in the innovative drug track, and their research and development pipelines involve stem cell drugs, genetic drugs, and drugs for mental illness
.
In addition, there are 4 companies invested in the field of in vitro diagnostics, and 3 companies in the field of interventional medical devices
.
From the perspective of the financing amount of a single project, the medical and health enterprises that have invested more than 100 million yuan mainly include companies such as Beilai Bio, Saipu Instrument, and Antikang Bio
.
Among them, Beilai Bio announced on April 15 that it has completed hundreds of millions of B rounds and B+ rounds of financing.
Investors include SDIC Ventures, Detong Capital, New Hope, etc.
, with a total financing of about 300 million yuan
.
The company is an enterprise dedicated to stem cell and regenerative medicine research, research and development of new stem cell drugs and clinical transformation.
It has established a comprehensive and stable production process of stem cell preparations and a strict and perfect quality control system.
Refractory diseases, as well as unmet clinical needs in the fields of malignant tumors and other fields, carry out product pipeline layout
.
On April 13, Saipu Instruments announced the completion of the A+ round of financing of over 100 million yuan.
This round of financing was jointly invested by Sunshine Ronghui, Dongfang Jiafu, and Jiale Capital, and the old shareholders Yuanhe Holdings and Shun Capital continued to invest
.
The funds obtained will be used for the integration and upgrading of the company's core business
.
The company focuses on the field of high-end biomedical consumables, and is committed to providing global customers with high-quality consumables and customized services in molecular diagnosis, cell culture, immunotherapy,
etc.
For another example, Antikang Bio has recently completed a 100 million yuan Pre-A round of financing led by Tongchuang Weiye, Langmafeng Ventures, Shulan Junjie Capital and Jiaxing Science and Technology City High Investment
.
The company is an enterprise focusing on the research and development of innovative respiratory tract anti-infection drugs.
The funds raised this time will be used to promote and expand the research and development of new respiratory tract anti-infective drug clinical pipelines, and make every effort to accelerate the entry of domestic oral anti-new crown specific drug CN-2021 into clinical and global business.
expand
.
CN-2021 is a national class 1 new drug with independent intellectual property rights optimized on the basis of the structure of Pfizer’s nelmatevir.
Preclinical research data shows that CN-2021 has the potential of Best-in-Class drugs with the same target: Nematevir control, high exposure, long half-life, high therapeutic index
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.